Aphasia, AnomicNCT04138433
Mechanisms Underlying Spoken Language Production
A study testing Real tDCS in people with Aphasia, Anomic, run by University College London Hospitals at 1 site in United Kingdom.
Trial summary
Most of us take being able to communicate for granted. Anomia (word finding problems) after stroke can cause profound frustration and anxiety for patients and families. Some people recover; many don't. ~ 250,000 people in the UK have chronic speech and language problems post-stroke. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Aphasia, Anomic
- What is being tested?
- Real tDCS
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 30 Nov 2017to 30 Jan 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- English native speakers
- Over the age of 18
- 12 months or more after aphasic stroke
- Able to provide informed consent
Who cannot join
- Significant medical or psychiatric co-morbidity
- Clinical or neuroimaging evidence of significant multifocal cerebral disease
- Contraindications to tdcs
- Contraindications to MRI
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Institute of Cognitive Neuroscience, University College London
London, Greater London, WC1N 3AZ
About this study
Official title: Mechanisms Underlying Spoken Language Production: Facilitating Frontal Brain Networks Following Aphasic Stroke
Most of us take being able to communicate for granted. Anomia (word finding problems) after stroke can cause profound frustration and anxiety for patients and families. Some people recover; many don't. ~ 250,000 people in the UK have chronic speech and language problems post-stroke. This project will investigate how treatment for these people might be improved. The brain's speech areas can be stimulated using transcranial direct current stimulation (tDCS). The kit is simple; a battery powering electrodes placed on the scalp. Healthy people who had tDCS while naming pictures could find words quicker and their speech areas responded more efficiently. How it affects aphasic stroke patients' brain function is unknown.
Read the detailed description
All suitable participants will be living in the community and may have already consented to previous research projects and their details identified via the UCLH Aphasia Clinic run by the CI, which will act as an NHS PIC, or via the stroke volunteer database at the Wellcome Trust Centre for Neuroimaging, run by Professor Cathy Price (Research approved by the National Hospital of Neurology and Neurosurgery and the Institute of Neurology joint ethics committee, study number: NO32.
The initial approach to potential participants for this project will be made by The Chief Investigator Dr Jenny Crinion. If the participant agrees a member of the team will discuss with them the details of the project. Patient groups may be approached directly by the CI and RAs via stroke clubs etc. All participants will be formally consented at UCL.
Healthy subjects will be recruited by the CI and RAs via the volunteer database at the WTCN or ICN, and by asking relatives/carers of the patients if they wish to be involved (more likely to be matched for age and other factors). Potential participants in research databases have already consented to be approached for further research.
Part 1: Activation and modulation of residual inferior frontal gyrus (IFG) in aphasia
Aims: to examine connectivity within regions of the brain associated with spoken word retrieval (a "domain-specific" process) and more general cognitive control ("domain-general" processing) in aphasic stroke patients.
Hypotheses: following aphasic stroke a functionally selective network core for spoken word naming (i.e. domain specific for language) lies within (i) Broca's area, in patients with brain lesions sparing Broca's area (ii) right inferior frontal gyrus, in patients with damage to Broca's area.
Experimental design and predictions:
Patients with a chronic speech and language impairment (aphasia) following stroke will be divided into those with lesions affecting Broca's area, and those whose lesions lie elsewhere. They will receive brain stimulation, transcranial direct current stimulation (tDCS, which involves placing battery-operated electrodes on the participant's scalp), or sham stimulation, while completing an object naming task (to test domain-specific processing) and a non-linguistic task which measures performance related to domain-general cognitive processing. Both tasks will have "hard" and "easy" levels which are matched for difficulty across tasks. In the naming task, difficulty will be manipulated by providing different types of cues to assist with object naming. Extensive piloting of the stimuli and procedure in both healthy participants and aphasic stroke patients will ensure that the tests are suitable for the proposed research.
Participants will complete the experiment in an MRI scanner in order to measure brain activity in the domain-specific and domain-general neural networks during the linguistic and non-linguistic tasks.
List of all data to be collected
- Personal demographic data including: sex, age, contact details etc.
- Clinical data including: aphasic syndrome subtype, time since onset of symptoms, past medical history, current medications, contra-indications to MRI/fMRI/tDCS, etc.
- Language assessment scores (CAT).
- Naming scores.
- fMRI responses when speaking and at rest.
- High-resolution structural MRI scans to define area and volume of infarct
- Side-effects from stimulation/sham (Adverse Event data).
- Consent forms. The non-functional imaging data will be recorded on a Case Report Form (CRF) kept by the CI.
Collection/Storage
Any data initially collected on paper will be transferred to electronic format. The paper data (including a copy of the consent form) is stored in a locked cabinet at the ICN which only the CI and named collaborators will have access to. The electronic data is password protected and pseudoanonymized. The CI will be the custodian of the data after the trial is completed. Data will be kept for 10 years after the completion of the study, in line with UCL policy. The functional/structural imaging data (5, 6) will be stored indefinitely at the WTCN, this will be password protected. These are extremely rich data sets and may be used in future analyses/metanalyses. Only members of the research team will have access to the data. The CI will act as custodian of the data.
Monitoring and Auditing
The Chief Investigator will ensure there are adequate quality and number of monitoring activities conducted by the study team. This will include adherence to the protocol, procedures for consenting and ensure adequate data quality. The Chief Investigator will inform the sponsor should he/she have concerns which have arisen from monitoring activities, and/or if there are problems with oversight/monitoring procedures. An independent data monitoring committee (DMC) will be set up to deal with patient safety issues related to this project.
The data to be monitored by the DMC will include: language outcome scores (CAT) and Adverse Event Recording Forms. All adverse events will be recorded by the CI and passed on to the DMC and will follow the UCL protocol for reporting of adverse events in a single centre trial. The main function of the committee will be to determine if there is an excess of seizures (adverse events) in either patient group. There are no plans to stop the project early unless this is due to an excess of adverse events.
- Conditions
- Aphasia, Anomic
- Being tested
- Real tDCS, Sham tDCS
- Medical subject headings
- Anomia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Real tDCSDevice
Also called Brain Stimulation
Anodal tDCS 2 ma
Sham tDCSDevice
Also called Brain Stimulation
Sham tDCS 2 ma
| Study group | Role | What they receive |
|---|---|---|
| Real tDCS | Experimental | fMRI task plus anodal tDCS Receives: Device: Real tDCS |
| Sham tDCS | Sham comparator | fMRI task plus sham tDCS Receives: Device: Sham tDCS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Naming Speed
change in Tailor-made object naming test,
Measured: change from baseline to 20 minutes during and 20 minutes post tDCS intervention
Secondary outcomes (1)
Higher accuracy in naming
change in scores from tailor-made object naming tests
Measured: change from baseline to 20 minutes during and 20 minutes post tDCS intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Oct 2019
- Study start30 Nov 2017
- Primary completion30 Jan 2022
- Study completion30 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aphasia, AnomicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- University College London Hospitals
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jenny Crinion, University College, London
- Investigators
- Jennifer Crinion, Dr, Principal investigator, University College, London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04138433
- Sponsor's protocol ID
- 160106
- Status last verified
- May 2023
- First submitted
- 24 Oct 2016
- Last updated
- 11 May 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mechanisms Underlying Spoken Language Production: Facilitating Frontal Brain Networks Following Aphasic Stroke
- ClinicalTrials.gov ID
- NCT04138433
- Acronym / sponsor ID
- 160106
- Conditions
- Aphasia, Anomic
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 36 participants (actual)
- Lead sponsor
- University College London HospitalsUniversity, hospital or other
- Study start
- 30 Nov 2017 (actual)
- Primary completion
- 30 Jan 2022 (actual)
- Study completion
- 30 Jan 2022 (actual)
- First posted
- 24 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Most of us take being able to communicate for granted. Anomia (word finding problems) after stroke can cause profound frustration and anxiety for patients and families. Some people recover; many don't. ~ 250,000 people in the UK have chronic speech and language problems post-stroke. This project will investigate how treatment for these people might be improved. The brain's speech areas can be stimulated using transcranial direct current stimulation (tDCS). The kit is simple; a battery powering electrodes placed on the scalp. Healthy people who had tDCS while naming pictures could find words quicker and their speech areas responded more efficiently. How it affects aphasic stroke patients' brain function is unknown.
Detailed description
All suitable participants will be living in the community and may have already consented to previous research projects and their details identified via the UCLH Aphasia Clinic run by the CI, which will act as an NHS PIC, or via the stroke volunteer database at the Wellcome Trust Centre for Neuroimaging, run by Professor Cathy Price (Research approved by the National Hospital of Neurology and Neurosurgery and the Institute of Neurology joint ethics committee, study number: NO32.
The initial approach to potential participants for this project will be made by The Chief Investigator Dr Jenny Crinion. If the participant agrees a member of the team will discuss with them the details of the project. Patient groups may be approached directly by the CI and RAs via stroke clubs etc. All participants will be formally consented at UCL.
Healthy subjects will be recruited by the CI and RAs via the volunteer database at the WTCN or ICN, and by asking relatives/carers of the patients if they wish to be involved (more likely to be matched for age and other factors). Potential participants in research databases have already consented to be approached for further research.
Part 1: Activation and modulation of residual inferior frontal gyrus (IFG) in aphasia
Aims: to examine connectivity within regions of the brain associated with spoken word retrieval (a "domain-specific" process) and more general cognitive control ("domain-general" processing) in aphasic stroke patients.
Hypotheses: following aphasic stroke a functionally selective network core for spoken word naming (i.e. domain specific for language) lies within (i) Broca's area, in patients with brain lesions sparing Broca's area (ii) right inferior frontal gyrus, in patients with damage to Broca's area.
Experimental design and predictions:
Patients with a chronic speech and language impairment (aphasia) following stroke will be divided into those with lesions affecting Broca's area, and those whose lesions lie elsewhere. They will receive brain stimulation, transcranial direct current stimulation (tDCS, which involves placing battery-operated electrodes on the participant's scalp), or sham stimulation, while completing an object naming task (to test domain-specific processing) and a non-linguistic task which measures performance related to domain-general cognitive processing. Both tasks will have "hard" and "easy" levels which are matched for difficulty across tasks. In the naming task, difficulty will be manipulated by providing different types of cues to assist with object naming. Extensive piloting of the stimuli and procedure in both healthy participants and aphasic stroke patients will ensure that the tests are suitable for the proposed research.
Participants will complete the experiment in an MRI scanner in order to measure brain activity in the domain-specific and domain-general neural networks during the linguistic and non-linguistic tasks.
List of all data to be collected
- Personal demographic data including: sex, age, contact details etc.
- Clinical data including: aphasic syndrome subtype, time since onset of symptoms, past medical history, current medications, contra-indications to MRI/fMRI/tDCS, etc.
- Language assessment scores (CAT).
- Naming scores.
- fMRI responses when speaking and at rest.
- High-resolution structural MRI scans to define area and volume of infarct
- Side-effects from stimulation/sham (Adverse Event data).
- Consent forms. The non-functional imaging data will be recorded on a Case Report Form (CRF) kept by the CI.
Collection/Storage
Any data initially collected on paper will be transferred to electronic format. The paper data (including a copy of the consent form) is stored in a locked cabinet at the ICN which only the CI and named collaborators will have access to. The electronic data is password protected and pseudoanonymized. The CI will be the custodian of the data after the trial is completed. Data will be kept for 10 years after the completion of the study, in line with UCL policy. The functional/structural imaging data (5, 6) will be stored indefinitely at the WTCN, this will be password protected. These are extremely rich data sets and may be used in future analyses/metanalyses. Only members of the research team will have access to the data. The CI will act as custodian of the data.
Monitoring and Auditing
The Chief Investigator will ensure there are adequate quality and number of monitoring activities conducted by the study team. This will include adherence to the protocol, procedures for consenting and ensure adequate data quality. The Chief Investigator will inform the sponsor should he/she have concerns which have arisen from monitoring activities, and/or if there are problems with oversight/monitoring procedures. An independent data monitoring committee (DMC) will be set up to deal with patient safety issues related to this project.
The data to be monitored by the DMC will include: language outcome scores (CAT) and Adverse Event Recording Forms. All adverse events will be recorded by the CI and passed on to the DMC and will follow the UCL protocol for reporting of adverse events in a single centre trial. The main function of the committee will be to determine if there is an excess of seizures (adverse events) in either patient group. There are no plans to stop the project early unless this is due to an excess of adverse events.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Real tDCS | Experimental | Device: Real tDCSfMRI task plus anodal tDCS |
| Sham tDCS | Sham comparator | Device: Sham tDCSfMRI task plus sham tDCS |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
Key exclusion criteria (4 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Real tDCSAlso: Brain StimulationAnodal tDCS 2 ma | Device | Real tDCS |
| Sham tDCSAlso: Brain StimulationSham tDCS 2 ma | Device | Sham tDCS |
Primary outcome
Change in Naming Speed
Time frame: change from baseline to 20 minutes during and 20 minutes post tDCS intervention
change in Tailor-made object naming test,
1 secondary outcome
Higher accuracy in naming
Time frame: change from baseline to 20 minutes during and 20 minutes post tDCS intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 May 2023.
- Individual participant dataSharing planned: No
Related trials for Aphasia, Anomic
RecruitingPhase 2
Comparing Traditional Semantic Feature Analysis (tSFA) and Semantic Feature Analysis + Metacognitive Strategy Training (SFA+MST)
Aphasia, Aphasia Following Cerebral Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jennifer Crinion, Dr principal investigator
University College, London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Real tDCS in people with Aphasia, Anomic, run by University College London Hospitals at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Naming Speed (time frame: change from baseline to 20 minutes during and 20 minutes post tDCS intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2023; AzTrials last refreshed its copy on 27 Oct 2026.